The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol
3‐kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth …

Therapies directed at endocrine receptors and human epidermal growth factor receptor 2
are important treatment options for patients with breast cancer; however, drug resistance …

Background Since the publication of the Bolero-2 trial, everolimus has entered the routine
care for advanced endocrine resistant luminal breast cancer (BC). We evaluated our …

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has
brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have …

Although patients with hormone receptor (HR)–positive breast cancer are successfully
treated with endocrine therapy, many tumors go on to develop resistance to these agents …

Advances in targeted therapies have improved progression-free and overall survival in
women with metastatic breast cancer; however, regardless of efficacy, resistance almost …

The inhibitors of mammalian target of rapamycin (mTOR) have documented antitumor
activity via disruption of various signaling pathways leading to impaired cellular growth …

Background: Breast cancer cells can develop resistance to standard hormonal treatment
and chemotherapy with the activation of the mTOR pathway; this is supported by results of …

Introduction: The phosphoinositide triphosphate kinase (PI3K)/AKT/mammalian target of
rapamycin (mTOR) is a central regulatory pathway involved in cell proliferation, growth …

Abstract Everolimus (RAD001, Afinitor®) is an oral, selective mTOR inhibitor recently
approved by the US-FDA in combination with exemestane for treatment of hormone receptor …